Abstract:In order to efficiently control the progression of atherosclerosis, 37pA‐LNP/6877002 and 37pA‐PtLNP are constructed to regulate the plaque microenvironment. 37pA‐PtLNP can effectively scavenge intracellular reactive oxygen species (ROS) of inflammatory macrophage in plaque. 37pA‐LNP/6877002 can inhibit the activities of tumor necrosis factor receptor‐associated factor 6 (TRAF6) to modestly decrease the proportion of the proinflammatory macrophage phenotype (reduce the expression of CD86 and iNOS). The combination of 37pA‐PtLNP and 37pA‐LNP/6877002 can achieve satisfactory stabilization of plaques with minimal progression. Chronic inflammatory microenvironment is the predominant milieu that promotes the progression of atherosclerosis (AS). However, targeted regulation of the chronic proinflammatory milieu still needs to be improved. In this study, macrophage‐targeting nanosystems composed of 37pA peptide embedded–Pt lipid nanoparticles (37pA‐PtLNP) and tumor necrosis factor‐associated factor 6 (TRAF6) inhibitor (6877002)‐loaded poly(ε‐caprolactone)‐b‐polyethylene glycol‐b‐poly(ε‐caprolactone) (PCEC) are constructed with 37pA peptide embedded–lipid coating (37pA‐LNP/6877002), to stabilize atherosclerotic lesions. The cooperative regulation effects of these nanosystems in achieving reactive oxygen species (ROS) scavenging and inflammatory signaling inhibition are investigated. 37pA‐PtLNP effectively scavenges several ROS, however, also promotes the expression of iNOS. The introduction of 37pA‐LNP/6877002 inhibits the activities of TRAF6, a downstream intracellular factor of the CD40L‐CD40‐TRAF6 axis, to decrease the proportion of the proinflammatory M1 macrophage phenotype, which is further downregulated by combined treatment with 37pA‐PtLNP. The combination of 37pA‐PtLNP and 37pA‐LNP/6877002 not only counteracts 37pA‐PtLNP–induced iNOS upregulation but also alleviates the chronic inflammatory microenvironment by reducing the expression of proinflammatory cytokines and chemokines. The anti‐AS efficacy in vivo on ApoE−/− mice further demonstrates that the combination of 37pA‐PtLNP and 37pA‐LNP/6877002 targetedly modulates the atherosclerotic plaque microenvironment, achieving stabilization of lesions with minimal progression. This study provides a promising strategy for AS management.

Dynamically Enhancing Plaque Targeting Via a Positive Feedback Loop Using Multifunctional Biomimetic Nanoparticles for Plaque Regression.

Aiming at Early-Stage Vulnerable Plaques: A Nanoplatform with Dual-Mode Imaging and Lipid-Inflammation Integrated Regulation for Atherosclerotic Theranostics

ROS-responsive Biomimetic Nanovesicles to Plaque Microenvironment in Targeted Therapy of Atherosclerosis

Plaque-hyaluronidase-responsive High-Density-lipoprotein-mimetic Nanoparticles for Multistage Intimal-Macrophage-targeted Drug Delivery and Enhanced Anti-Atherosclerotic Therapy.

Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: A dual cell therapy to regress plaques

Targeting Nanoplatform for Atherosclerosis Inhibition and Degradation via a Dual‐Track Reverse Cholesterol Transport Strategy

Pro-efferocytosis biomimetic nanocomplexes for targeted atherosclerosis therapy through promoting macrophage re-polarization and inhibiting senescence

Platelet Membrane Biomimetic Nanoparticles Combined With UTMD to Improve the Stability of Atherosclerotic Plaques

Plaque Macrophage‐Targeting Nanosystems with Cooperative Co‐Regulation of ROS and TRAF6 for Stabilization of Atherosclerotic Plaques

Platelet‐Mimicking Therapeutic System for Noninvasive Mitigation of the Progression of Atherosclerotic Plaques

Application of Therapeutical Nanoparticles with Neutrophil Membrane Camouflaging for Inflammatory Plaques Targeting against Atherosclerosis

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

Targeting Theranostics of Atherosclerosis by Dual‐Responsive Nanoplatform via Photoacoustic Imaging and Three‐In‐One Integrated Lipid Management

Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis

Nanoparticle Functionalization with Platelet Membrane Enables Multifactored Biological Targeting and Detection of Atherosclerosis

β-Cyclodextrin and Hyaluronic Acid-Modified Targeted Nanodelivery System for Atherosclerosis Prevention

Abstract 13: Development of Functionalized Nanoparticle Platform for Reducing Atherosclerosis

Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis

Theranostic nanoplatform to target macrophages enables the inhibition of atherosclerosis progression and fluorescence imaging of plaque in ApoE(−/−) mice

Devouring Atherosclerotic Plaques: The Engineered Nanorobot Rousing Macrophage Efferocytosis by a Two‐Pronged Strategy

Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.